Cancer chemopreventive effect of phenothiazines and related tri-heterocyclic analogues in the 12-O-tetradecanoylphorbol-13-acetate promoted Epstein-Barr virus early antigen activation and the mouse skin two-stage carcinogenesis models

Pharmacological Research

Volumn 49, Issue 2, 2004, Pages 161-169

  Azuine, Magnus A ^a   Tokuda, Harukuni ^b   Takayasu, Junko ^b   Enjyo, Fumio ^b   Mukainaka, Teruo ^b   Konoshima, Takao ^c   Nishino, Hoyoku ^b   Kapadia, Govind J ^a  

^a HOWARD UNIVERSITY   (United States)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Cancer; Chemoprevention; Peroxynitrite; Phenothiazines; Phenoxazine; Structure activity relationships

Indexed keywords

1 CHLORO 4 PROPOXY 9H THIOXANTHEN 9 ONE; 2 ACETYLPHENOTHIAZINE; 2 AMINO 7 ETHYL 5 OXO 5H(1) BENZOPYRANO[2,3 B]PYRIDINE 3 CARBONITRILE; 2 AMINO 7,9 DIMETHYL 5 OXO 5H(1) BENZOPYRANO[2,3 B]PYRIDINE 3 CARBONITRILE; 2 CHLOROTHIOXANTHONE; 2 ISOPROPYL 8H THIOXANTHEN 9 ONE; 2,4 DIETHYL 9H THIOXANTHEN 9 ONE; 3 ACETYL 2 METHYL 5H(1) BENZOPYRANO[2,3 B]PYRIDIN 5 ONE; 9 OXO 9H THIOXANTHENE 3 CARBONITRILE 10,10 DIOXIDE; 9 OXO 9H THIOXANTHENE 3 CARBOXYLIC ACID 10,10 DIOXIDE; ACETOPROMAZINE MALEATE; CHLORPROMAZINE; CHLORPROTHIXENE; DIMETHYLBENZ[A]ANTHRACENE; ETHYLPROPAZINE; FLUPHENAZINE; HETEROCYCLIC COMPOUND; PEROXYNITRITE; PHENOTHIAZINE; PHENOTHIAZINE DERIVATIVE; PHENOXANTHIN; PHENOXAZINE DERIVATIVE; PHORBOL 13 ACETATE 12 MYRISTATE; PROMETHAZINE; THIANTHRENE; THIOXANTHONE; TIOTIXENE; TRIFLUOPERAZINE; TUMOR PROMOTER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INCIDENCE; CANCER STAGING; CONTROLLED STUDY; DRUG DETERMINATION; EPSTEIN BARR VIRUS; EXPERIMENTAL MODEL; FEMALE; LATENT PERIOD; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN CARCINOGENESIS; TOPICAL TREATMENT; TREATMENT OUTCOME; TUMOR PROMOTION;

EID: 0344010203     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phrs.2003.07.014     Document Type: Article

References (47)

1. Wattenberg L.W. Chemoprevention of cancer. Cancer Res. 45:1985;1-45.
2. Azuine M.A., Bhide S.V. Adjuvant chemoprevention of experimental cancer: catechin and dietary turmeric in forestomach and oral cancer models. J. Ethnopharmacol. 44:1994;211-217.
3. Lippman S.M., Benner S.E., Hong W.K. Cancer chemoprevention. J. Clin. Oncol. 12:1994;851-873.
4. Szarka C.E., Grana G., Engstrom P.F. Chemoprevention of cancer. Curr. Prob. Cancer. 18:1994;6-79.
5. Perchellet J.P., Perchellet E.M. Antioxidants and multistage carcinogenesis in mouse skin. Free Rad. Biol. Med. 7:1989;377-408.
6. Gordon M, editor. Medicinal chemistry, vol. 4.; Psychopharmacological agents, vol. 3. New York: Academic Press; 1974.
7. Gilman AG, Rall TW, Nies AS, et al., (Eds). Goodman and Gilman's the pharmacological basis of therapeutics. New York: Pergamon Press; 1990.
8. Katz J., Kunofsky S., Patton R.E., Allaway N.C. Cancer mortality among patients in New York mental hospitals. Cancer. 12:1967;2194-2199.
9. Polliack A., Levij I.S. Antineoplastic effect of chlorpromazine in chemical carcinogenesis in the hamster cheek pouch. Cancer Res. 32:1972;1912-1915.
10. Mostafa M.H., Weisburger E.K. Effect of chlorpromazine hydrochloride on carcinogen-metabolizing enzymes: liver microsomal dimethylnitrosamine demethylase, 4-dimethylaminoazobenzene reductase, and aryl hydrocarbon hydroxylase. J. Natl. Cancer Inst. 64:1980;925-929.
11. Takada K., Zur Hausen H. Induction of Epstein-Barr virus antigens by tumor promoters for epidermal and nonepidermal tissues. Int. J. Cancer. 33:1984;491-496.
12. Azuine M.A., Kayal J.J., Bhide S.V. Protective role of aqueous turmeric extract against mutagenicity of direct-acting carcinogens as well as benzo(a)pyrene-induced genotoxicity and carcinogenicity. J. Cancer Res. Clin. Oncol. 118:1992;447-452.
13. De Flora S. Mechanisms of mutagenesis and carcinogenesis. Mutat. Res. 402:1998;151-158.
14. Kellof G.J. Perspectives on cancer chemoprevention research and drug development. Adv. Cancer Res. 78:2000;199-334.
15. Kondo A., Morimoto T., Okazaki K. Detection of antitumor promoting activity in Raji cells carrying Epstein-Barr virus genome by immunoblotting analysis. Biosci. Biotechnol. Biochem. 62:1998;377-379.
16. Ishida J., Kozuka M., Wang H., Konoshima T., Tokuda H., Okuda M.et al. Antitumor-promoting effects of cyclic diarylheptanoids on Epstein-Barr virus activation and two-stage mouse skin carcinogenesis. Cancer Lett. 159:2000;135-140.
17. Diallo B., Vanhaelen M., Vanhaelen-Fastre R., Konoshima T., Kozuka M., Tokuda H. Studies on inhibitors of skin tumor promotion: inhibitory effects of triterpenes from Cochlospermum tinctorium on Epstein-Barr virus activation. J. Nat. Prod. 52:1989;879-881.
18. Ito Y., Yanasse S., Fujita J., Harayama T., Takashima M., Imanaka H. A short-term in vitro assay for promoter substances using human lymphoblastoid cells latently infected with Epstein-Barr virus. Cancer Lett. 13:1981;29-37.
19. Takaishi Y., Ujita K., Tokuda H., Nishino H., Iwashima A., Fujita T. Inhibitory effects of dihydroagarofuran sesquiterpenes on Epstein-Barr virus activation. Cancer Lett. 65:1992;19-26.
20. Kapadia G.J., Tokuda H., Konishima T., Nishino H. Chemoprevention of lung and skin cancer by Beta vulgaris (beet) root extract. Cancer Lett. 100:1996;211-214.
21. Motohashi N., Gollapudi S.R., Emrani J., Bhattiprolu K.R. Antitumor properties of phenothiazines. Cancer Invest. 9:1991;305-319.
22. Wuonola M.A., Palfreyman M.G., Motohashi N., Kawase M., Gabay S., Nasca J.et al. The primary in vitro antitumor screening of "half-mustard type" phenothiazines. Anticancer Res. 17:1997;3409-3423.
23. Wuonola M.A., Palfreyman M.G., Motohashi N., Kawase M., Gabay S., Gupta R.R.et al. The primary in vitro anticancer screening of "half-mustard type" phenothiazines in NCI's revised anticancer screening paradigm. Anticancer Res. 18:1998;337-348.
24. Tanaka M., Wayda K., Molnar J., Parkanyi C., Aaron J.J., Motohashi N. Antimutagenicity of benzo[a]phenothiazines in chemically induced mutagenesis. Anticancer Res. 17:1997;839-842.
25. Kapadia G.J., Balasubramanian V., Tokuda H., Iwashima A., Nishino H. Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced Epstein-Barr virus early antigen activation by natural colorants. Cancer Lett. 115:1997;173-178.
26. Kapadia G.J., Tokuda H., Sridhar R., Balasubramanian V., Takayasu J., Bu P.et al. Cancer chemopreventive activity of synthetic colorants used in food, pharmaceuticals and cosmetic preparations. Cancer Lett. 129:1998;87-95.
27. Lehnert S. Cytotoxicity of phenothiazines: studies with aerated and hypoxic cells. Res. Commun. Chem. Pathol. Pharmacol. 56:1987;361-374.
28. Melvin H.V.W., Steven H.P. Inhibition of the growth of mouse melanoma by chlorpromazine. Cancer Res. 29:1969;1952-1955.
29. Petri I.B., Szekeres E., Varga E., Berek I., Molnar J., Berek L.et al. Immunomodulating activities on cellular cytotoxicity and the blast transformation of human lymphocytes by 10-[n-(phthalimido)alkyl-2-substituted- 10H-phenothiazines and 1-(2-chloroethyl)-3-(2-substituted-10H-phenothiazin-10- yl)alkyl-1-ureas. Anticancer Res. 16:1996;1247-1250.
30. Komatsu N., Motohashi N., Fujimaki M., Molnar J. Induction of a protective immunity in mice against Escherichia coli by phenothiazines, 10-[n-(phthalimido)alkyl]-2-substituted-10H-phenothiazines and 1-(2-chloroethyl)-3-(2-substituted-10H-phenothiazines-10-yl)alkyl-1-ureas. In Vivo. 11:1997;13-16.
31. Sakagami H., Takahashi H., Yoshida H., Yamamura M., Fukuchi K., Gomi K. et al. Induction of DNA fragmentation in human myelogenous leukemic cell lines by phenothiazine-related compounds. Anticancer Res. 15:1995;2533-2540.
32. Shenoy M.A., Singh B.B. Cytotoxic and radiosensitizing effects of chlorpromazine hydrochloride in sarcoma 180A. Ind. J. Exp. Biol. 18:1980;791-795.
33. Kittle J.D. Jr., Calle L.M., Sullivan P.D. The effect of substituted phenothiazines on the mutagenicity of benzo(a)pyrene. Mutat. Res. 80:1981;259-264.
34. Tanaka M., Wayda K., Molnar J., Motohashi N. Antimutagenicity of benzo[a]phenothiazines in chemically induced mutagenesis. Anticancer Res. 16:1996;3625-3628.
35. Tanaka M., Molnar J., Kidd S. Antimutagenicity of phenothiazine-metal co-ordination complexes in chemically induced mutagenesis. Anticancer Res. 17:1997;381-385.
36. Kapadia G.J., Balasubramanian V., Tokuda H., Konoshima T., Takasaki M., Koyama J.et al. Anti-tumor promoting effects of naphthoquinone derivatives on short term Epstein-Barr early antigen activation assay and in mouse skin carcinogenesis. Cancer Lett. 113:1997;47-53.
37. Ito C., Itoigawa M., Tan H.T., Tokuda H., Yang Mou X., Mukainaka T.et al. Anti-tumor promoting effects of isoflavonoids on Epstein-Barr virus activation and two-stage mouse skin carcinogenesis. Cancer Lett. 152:2000;187-192.
38. Zografi G., Zarenda I. The surface activity of phenothiazine derivatives at the air-solution interface. Biochem. Pharmacol. 15:1966;591-598.
39. Ford J.M., Prozialeck W.C., Hait W.N. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol. Pharmacol. 35:1989;105-115.
40. Wesolowska O., Molnar J., Motohashi N., Michalaki K. Inhibition of P-glycoprotein transport function by N-acylphenothiazines. Anticancer Res. 22:2002;2863-2867.
41. Mucsi I., Varga A., Kawase M., Motohashi N., Molnar J. Interaction between various resistance modifiers and apoptosis inducer 12H-benzo(alpha) phenothiazine. Anticancer Res. 22:2002;2833-2836.
42. Motohashi N., Mitscher L.A., Meyer R. Potential antitumor phenoxazines. Med. Res. Rev. 11:1991;239-294.
43. Shimamoto T., Tomoda A., Ishida R., Ohyashiki K. Antitumor effects of a novel phenoxazine derivative on human leukemia cell lines in vitro and in vivo. Clin. Cancer Res. 7:2001;704-708.
44. Abe A., Yamane M., Tomoda A. Prevention of growth of human lung carcinoma cells and induction of apoptosis by a novel phenoxazinone, 2-amino-4,4alpha-dihydro-4alpha,7-dimethyl-3H-phenoxazine-3-one. Anticancer Drugs. 12:2001;377-382.
45. Mori H., Honda K., Ishida R., Nohira T., Tomoda A. Antitumor activity of 2-amino-4,4alpha-dihydro-4alpha,7-dimethyl-3H-phenoxazine-3-one against Meth A tumor transplanted into BALB/c mice. Anticancer Drugs. 11:2000;653-657.
46. Kellof G.J., Sigman C.C., Greenwald P. Cancer chemoprevention: progress and promise. Eur. J. Cancer. 35:1999;1755-1762.
47. van Stolk R., Stoner G., Hayton W.L., Chan K., DeYoung B., Kresty L.et al. Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin. Cancer Res. 6:2000;78-89.